Fresh Tracks Therapeutics Inc
Change company Symbol lookup
Select an option...
FRTX Fresh Tracks Therapeutics Inc
DIDIY DiDi Global Inc
AWK American Water Works Company Inc
ASO Academy Sports and Outdoors Inc
GAB Gabelli Equity Trust
STRC Sarcos Technology and Robotics Corp
RLMD Relmada Therapeutics Inc
LMND Lemonade Inc
NAACW North Atlantic Acquisition Equity Warrant Exp 20 Oct 2025 *W EXP 10/20/2025
CG Carlyle Group Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology | Small Cap Blend
Company profile

Fresh Tracks Therapeutics, Inc., formerly Brickell Biotech, Inc., is a clinical-stage pharmaceutical company engaged in transforming patient lives through the development of differentiated prescription therapeutics. Its pipeline is focused on providing existing treatment paradigms and features several new molecular entities that inhibit novel targets with potential for autoimmune, inflammatory, and other debilitating diseases. The Company’s strategy is exploring therapies by identifying, pursuing, and developing therapeutics that can help people struggling with autoimmune, inflammatory and other debilitating diseases. Its pipeline includes FRTX-02, FRTX-10, Kinase Inhibitors and FRTX-03. Its lead program, FRTX-02, is a clinical-stage oral DYRK1A inhibitor for patients with autoimmune diseases to be administered in humans. Its FRTX-10 is a preclinical-stage stimulator of interferon genes (STING) inhibitor candidate. Its Kinase Inhibitors include compounds that inhibit prominent targets.

The symbol you entered, BBI, changed to FRTX.

Closing Price
$1.72
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
0

10-day average volume:
226,302
0

Display:

Providers:

UpdateCancel
6 providers
September 13, 2022
Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02

EQNX::TICKER_START (NASDAQ:BBI),(NASDAQ:FRTX), EQNX::TICKER_END FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing (Globe Newswire)

September 07, 2022
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics

EQNX::TICKER_START (NASDAQ:BBI),(NASDAQ:FRTX), EQNX::TICKER_END New name, logo, website, and branding reflect the Company's strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies (Globe Newswire)

August 11, 2022
Brickell Biotech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors...(Globe Newswire)

August 02, 2022
Brickell Biotech to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on August 11, 2022

EQNX::TICKER_START (NASDAQ:BBI), EQNX::TICKER_END Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics...(Globe Newswire)

July 20, 2022
Brickell Biotech Regains Compliance with Nasdaq Minimum Bid Price Requirement

EQNX::TICKER_START (NASDAQ:BBI), EQNX::TICKER_END Brickell Biotech, Inc. ("Brickell") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics...(Globe Newswire)

July 06, 2022
Brickell Biotech to Participate at William Blair Biotech Focus Conference 2022

EQNX::TICKER_START (NASDAQ:BBI), EQNX::TICKER_END Brickell Biotech, Inc. ("Brickell" or the "Company") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated...(Globe Newswire)

July 01, 2022
Brickell Biotech Announces 1-For-45 Reverse Stock Split

EQNX::TICKER_START (NASDAQ:BBI), EQNX::TICKER_END Brickell Biotech, Inc. ("Brickell" or the "Company") (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.